1. Home
  2. NFGC vs SLN Comparison

NFGC vs SLN Comparison

Compare NFGC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Found Gold Corp

NFGC

New Found Gold Corp

N/A

Current Price

$1.57

Market Cap

672.6M

ML Signal

N/A

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

N/A

Current Price

$9.95

Market Cap

678.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NFGC
SLN
Founded
2016
1994
Country
Canada
United Kingdom
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.6M
678.0M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
NFGC
SLN
Price
$1.57
$9.95
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
$4.26
★ $33.00
AVG Volume (30 Days)
782.7K
★ 885.1K
Earning Date
08-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $559,000.00
Revenue This Year
$994.66
N/A
Revenue Next Year
$230.05
$132.77
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.34
$4.19
52 Week High
$3.59
$17.58

Technical Indicators

Market Signals
Indicator
NFGC
SLN
Relative Strength Index (RSI) 41.21 30.63
Support Level $1.45 $4.70
Resistance Level $1.60 $11.06
Average True Range (ATR) 0.07 0.58
MACD -0.02 -0.16
Stochastic Oscillator 17.11 26.27

Price Performance

Historical Comparison
NFGC
SLN

About NFGC New Found Gold Corp

New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Companies exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: